Inhibition of simian varicella virus infection of monkeys by 1-(2-deoxy-2- fluoro-1-beta-D-arabinofuranosyl)-5-ethyluracil (FEAU) and synergistic effects of combination with human recombinant interferon-beta

Antiviral Res. 1990 Apr;13(4):165-74. doi: 10.1016/0166-3542(90)90035-6.

Abstract

1-(2-Deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-ethyluracil (FEAU) has been shown to be a highly effective inhibitor of Simian varicella virus infection in African green monkeys. Administration of FEAU by either intravenous injection or gavage at doses as low as 1 mg/kg/day prevented the development of rash and reduced viremia. The effective dose could be further reduced to 0.2 mg/kg/day when administered in combination with a sub-effective dose of human recombinant interferon-beta. No evidence of toxicity was seen in monkeys treated for 10 days with FEAU doses of 10 mg/kg/day when they were monitored by hematology and clinical chemistry tests and by clinical observations.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenoviridae Infections / prevention & control*
  • Adenoviruses, Simian / drug effects
  • Animals
  • Antiviral Agents / pharmacology*
  • Arabinofuranosyluracil / administration & dosage
  • Arabinofuranosyluracil / analogs & derivatives*
  • Arabinofuranosyluracil / pharmacology
  • Chlorocebus aethiops
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Humans
  • Injections, Intravenous
  • Interferon Type I / administration & dosage
  • Interferon Type I / pharmacology*
  • Recombinant Proteins
  • Uridine / analogs & derivatives*
  • Viremia / drug therapy

Substances

  • Antiviral Agents
  • Interferon Type I
  • Recombinant Proteins
  • Arabinofuranosyluracil
  • 1-(2-deoxy-2-fluoroarabinofuranosyl)-5-ethyluracil
  • Uridine